Table. Test results for 16 participants in a 2013 serosurvey in Kenya whose samples were positive for ZIKV by testing conducted in 2018*.
| Participant no. | Age, y | CDC ZIKV MAC ELISA P/N ratio (IgM) | ZIKV PRNT90 titer | DENV PRNT90 titer | Participant type | Final interpretation of case |
|---|---|---|---|---|---|---|
| 2 | 63 | 3.56 | 1:20 | <1:20 | Serosurvey | ZIKV |
| 3 | 50 | 10.00 | >1:320 | <1:20 | Serosurvey | ZIKV |
| 5 | 70 | 3.17 | 1:20 | <1:20 | Serosurvey | ZIKV |
| 10 | NA | 3.51 | 1:20 | <1:20 | Hospital | ZIKV |
| 31 | 51 | 5.50 | >1:320 | 1:20 | Serosurvey | ZIKV |
| 4 | 45 | 3.26 | <1:20 | 1:20 | Serosurvey | DENV |
| 7 | 36 | 8.65 | 1:20 | 1:320 | Serosurvey | DENV |
| 20 | 58 | 13.18 | 1:20 | 1:320 | Serosurvey | DENV |
| 25 | 45 | 3.70 | 1:20 | >1:320 | Serosurvey | DENV |
| 26 | 27 | 5.00 | 1:80 | >1:320 | Serosurvey | DENV |
| 27 | 42 | 3.20 | 1:80 | 1:320 | Serosurvey | DENV |
| 33 | 30 | 10.70 | 1:20 | 1:80 | Serosurvey | DENV |
| 1 | 32 | 4.49 | 1:20 | 1:20 | Serosurvey | Cross-reactive |
| 9 | 27 | 3.82 | 1:20 | 1:20 | Serosurvey | Cross-reactive |
| 30 | 58 | 3.20 | >1:320 | >1:320 | Serosurvey | Cross-reactive |
| 6 | 41 | 16.35 | 1:20 | ND | Serosurvey | Inconclusive |
*CDC, Centers for Disease Control and Prevention; DENV, dengue virus; MAC, IgM antibody capture; NA, not available; ND, not done due to insufficient specimen; PRNT90, plaque reduction neutralization test 90%; ZIKV, Zika virus.